ArticleCureus2023
An Erythrodermic Psoriasis Flare-Up With Staphylococcus Bacteremia Secondary to COVID-19 Infection: A Case Report.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Update on the Etiology and Pathogenesis of Erythrodermic Psoriasis.Journal of inflammation research · 2026Review
- Update on Erythrodermic Psoriasis: Proposal of a Management Algorithm by an Innovative Severity Evaluation Approach.Psoriasis (Auckland, N.Z.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythrodermic psoriasis (EP) is an autoimmune condition commonly manifested as cutaneous lesions, such as well-demarcated, erythematous, scaly plaques, notably on the extensor surfaces but sometimes present on the scalp, palms, and soles. Various triggering events are known to initiate flare-ups of previously well-controlled/dormant EP. In recent literature, the association of acutely exacerbated EP after symptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been well-described. Here, we present a case of EP with increased flaking and desquamation of the skin of the whole body (most notably on the palms and soles) after three weeks of symptomatic SARS-CoV-2 infection without any other evident trigger. We aim to describe the symptoms as well as the proper management of a patient afflicted with erythrodermic psoriasis in hopes of aiding future clinicians in the prompt diagnosis and treatment of such a patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.